Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.

Also called NCT01960179

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 361 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01960179
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01960179. Allocation not applicable; no masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2015-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
lixisenatide AVE0010
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01960179
Content hash
74d04262b2fcbe24896207d01312a89d9ee36277d6516401e98530acb621b514